Amendments to the Claims

Please cancel Claims 3-55. Please amend Claims 1 and 56. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

- 1. (Currently Amended) A method of testing for the remission stage of atopic dermatitis that is associated with a decrease in eosinophil cell number in a test subject <u>having atopic</u> <u>dermatitis</u>, said method comprising the steps of:
 - (a) measuring the expression level of the NOR-1 gene in the eosinophil cells of the test subject <u>having atopic dermatitis</u>; and
 - (b) comparing the expression level <u>measured</u> with that the expression level of the <u>NOR-1 gene</u> in the eosinophil cells of an the test subject during the exacerbation stage of atopic dermatitis exacerbation stage subject,

wherein the remission stage of atopic dermatitis that is associated with a decrease in eosinophil cell number is indicated by an increase in the level of NOR-1 gene expression in the eosinophil cells of the test subject <u>having atopic dermatitis</u> as compared with that <u>in the eosinophil cells of the test subject during the exacerbation stage of atopic dermatitis in an atopic dermatitis exacerbation subject</u>.

- 2. (Original) The testing method of claim 1, wherein the gene expression level is measured by cDNA PCR.
- 3.-55. (Canceled)
- 56. (Currently Amended) A method of assessing the effect of a therapy on the atopic dermatitis of an individual in the exacerbation stage of atopic dermatitis comprising:
 - (a) measuring the expression level of the NOR-1 gene in the eosinophil cells of the individual before and after the therapy; and
 - (b) comparing the expression level of the NOR-1 gene measured before the therapy to that measured after the therapy[[,]]; and
 - (c) determining whether the test subject has had a decrease in eosinophil cell number after the therapy,

wherein an increase in the NOR-1 gene expression level <u>and a decrease in eosinophil cell</u> <u>number</u> after the therapy compared to that before the therapy indicate <u>that the therapy has</u> <u>been effective</u> an improvement in the symptoms of the atopic dermatitis and a positive <u>effect of said therapy on the atopic dermatitis of the individual</u>.

57. (Previously Presented) The method of claim 56 wherein the NOR-1 gene expression level is measured by cDNA PCR.